GMGuy Morris

Guy Morris

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Guy Morris has a total of 47 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Long-Term Clinical and Radiographic Osseointegration Outcomes of a Highly Porous 3D-Printed Titanium Collar Compared with a Hydroxyapatite-Coated Collar in Megaprostheses

    by Hariharan Triplicane Dwarakanathan, Natalie Green, Thomas Haider, Iosif Pagkalos, Guy Morris, Rajesh Botchu, Lee M. Jeys

    This is a retrospective, single-center cohort study comparing the long-term radiographic osseointegration and aseptic loosening between a 3D-printed EPORE® collar and a prior generation HA-coated collar in endoprosthetic reconstructions. Achieving stable bone integration in endoprosthetic reconstructions remains challenging, with hydroxyapatite (HA)-coated collars being the only option available in the past. Earlier studies from our center have shown reliable and accelerated osseointegration at the bone–collar interface using a novel highly porous 3D-printed EPORE® collar system compared to a previously used HA-coated collar. Methods: Twenty-eight patients who underwent an implantation of endoprostheses utilizing the novel 3D-printed EPORE® collar system were case-matched to 24 patients who had previously undergone surgeries using a HA-coated collar. The mean age at surgery was 65.2 years (range: 17–95 years). Patients in the HA-coated collar group had a mean age of 63.8 years (range: 17–86 years), while those in the 3D-printed collar group had a mean age of 66.7 years (range: 32–95 years), with no statistically significant difference between groups (p = 0.876). A minimum radiological and clinical follow-up of 2 years was available in all included cases. Osseointegration was evaluated using postoperative plain radiographs in two planes based on a previously validated semi-quantitative score. Results: When aseptic loosening was used as the primary endpoint, no failures occurred in the 3D-printed EPORE® group during the study period. The overall rate of stem loosening (including both aseptic and septic causes) was 7% (2/28) in the 3D-printed group and 16% (4/24) in the HA-coated group. All cases of loosening in the 3D-printed cohort were related to septic failure. This translates into a 2-year aseptic-loosening-free survival of 100% in the 3D-printed group. When the radiographic osseointegration was analyzed as the endpoint, the rate of successful osseointegration was significantly higher in the 3D-printed group (92.9%, 26/28; 95% CI 76.5–99.1%) compared with the HA-coated group (70.8%, 17/24; 95% CI 48.9–87.4%; p = 0.04). The distribution of ongrowth scores also differed significantly between groups. The highest ongrowth score (grade 4) was achieved in 82.14% of 3D-printed implants (23/28; 95% CI 63.1–93.9%), compared with 37.5% of HA-coated implants (9/24; p = 0.0002). The time to achieve grade 4 ongrowth was significantly shorter in the 3D-printed cohort, with a median of 470 days (IQR 360–610), compared with 1482 days (IQR 1020–1860) in the HA-coated group (p < 0.0001). In addition, patients in the 3D-printed implant group had a significantly higher mean body mass index compared with the HA-coated group (32.51 vs. 28.36, p = 0.01). Conclusions: These results show that the novel highly porous 3D-printed EPORE® collars reduce aseptic loosening and accelerate extracortical bridging in endoprosthetic replacements. This benefit persisted even in higher BMI or revision contexts when compared to the previously used HA-coated collars.


  • Open Access

    Long Term Clinical and Radiographic Osseointegration Outcomes of a Highly Porous 3D Printed Titanium Collar for Megaprostheses Compared to a Previous Generation Ha Coated Collar

    by Hariharan Triplicane Dwarakanathan, Natalie Green, Thomas Haider, Iosif Pagkalos, Guy Morris, Rajesh Botchu, Lee M Jeys

    Achieving stable bone integration in megaprosthetic reconstructions remains challenging, with traditional hydroxyapatite (HA)-coated collars showing variable outcomes. This study compares long-term osseointegration and clinical performance of a novel 3D-printed porous collar (EPORE®) versus conventional HA-coated collars in 52 patients (28 with 3D-printed, 24 with HA-coated). Radiographic osseointegration was assessed using a validated scoring system, with follow-up exceeding two years. The 3D-printed group demonstrated significantly higher osseointegration rates (92.9% vs. 70.8%, p=0.04) and faster bone ongrowth (470 vs. 1482 days to full integration, p<0.0001), with 89.3% achieving the highest integration score compared to 37.5% in the HA group (p=0.0002). Notably, no aseptic loosening occurred with 3D-printed collars, while HA-coated collars had an 8% aseptic loosening rate. Despite higher BMI in the 3D-printed group (32.5 vs. 28.4, p=0.01), outcomes were superior, suggesting the porous design mitigates obesity-related risks. These findings indicate that 3D-printed collars enhance biological fixation, reduce loosening, and improve implant stability, particularly in complex revisions. This technology represents a significant advancement in megaprosthetic design, with potential to improve long-term outcomes in high-risk patients.

  • Open Access

    Improving oncological outcomes for pelvic bone sarcomas: Is it possible?

    by Minna K. Laitinen, Vineet J. Kurisunkal, Michael C. Parry, Guy V. Morris, Jonathan D. Stevenson, Lee M. Jeys


  • The size of local recurrence influences outcomes in chondrosarcoma: Significant impact observed in grade 2 tumours

    by G. Kask, M.K. Laitinen, M.C. Parry, V.J. Kurisunkal, G.V. Morris, J.D. Stevenson, L.M. Jeys


  • Enhancing surgical margins: A key to survival in pelvic chondrosarcoma

    by Minna K. Laitinen, Michael C. Parry, Guy V. Morris, Vineet J. Kurisunkal, Jonathan D. Stevenson, Lee M. Jeys


  • A pictographic guide for decision making in surgery for pelvic bone sarcoma

    by Raja Bhaskara Rajasekaran, Vineet Kurisunkal, Jonathan D. Stevenson, Michael C. Parry, Guy V. Morris, Lee M. Jeys


  • Open Access

    Can the Cartilaginous Thickness Determine the Risk of Malignancy in Pelvic Cartilaginous Tumors, and How Accurate is the Preoperative Biopsy of These Tumors?

    by Minna K. Laitinen, Michael C. BSc Parry, Guy V. MBChB Morris, Vineet Kurisunkal, Jonathan D. MBChB Stevenson, Lee M. Dsc Jeys

    Background: Peripheral osteochondral tumors are common, and the management of tumors presenting in the pelvis is challenging and a controversial topic. Some have suggested that cartilage cap thickness may indicate malignant potential, but this supposition is not well validated. Questions/purposes: (1) How accurate is preoperative biopsy in determining whether a peripheral cartilage tumor of the pelvis is benign or malignant? (2) Is the thickness of the cartilage cap as determined by MRI associated with the likelihood that a given peripheral cartilage tumor is malignant? (3) What is local recurrence-free survival (LRFS), metastasis-free survival (MFS), and disease-specific survival (DSS) in peripheral chondrosarcoma of the pelvis and is it associated with surgical margin? Methods: Between 2005 and 2022, 289 patients had diagnoses of peripheral cartilage tumors of the pelvis (either pedunculated or sessile) and were treated at one tertiary sarcoma center (the Royal Orthopaedic Hospital, Birmingham, UK). These patients were identified retrospectively from a longitudinally maintained institutional database. Those whose tumors were asymptomatic and discovered incidentally and had cartilage caps ≤ 1.5 cm were discharged (95 patients), leaving 194 patients with tumors that were either symptomatic or had cartilage caps > 1.5 cm. Tumors that were asymptomatic and had a cartilage cap > 1.5 cm were followed with MRIs for 2 years and discharged without biopsy if the tumors did not grow or change in appearance (15 patients). Patients with symptomatic tumors that had cartilage caps ≤ 1.5 cm underwent removal without biopsy (63 patients). A total of 82 patients (63 with caps ≤ 1.5 cm and 19 with caps > 1.5 cm, whose treatment deviated from the routine at the time) had their tumors removed without biopsy. This left 97 patients who underwent biopsy before removal of peripheral cartilage tumors of the pelvis, and this was the group we used to answer research question 1. The thickness of the cartilage cap was recorded from MRI and measuring to the nearest millimeter, with measurements taken perpendicular in the plane that best allowed the greatest measurement. Patient survival rates were assessed using the Kaplan-Meier method with 95% confidence intervals as median observation times to estimate MFS, LRFS, and DSS. Results: Of malignant tumors biopsied, in 49% (40 of 82), the biopsy result was recorded as benign (or was considered uncertain regarding malignancy). A malignant diagnosis was correctly reported in biopsy reports in 51% (42 of 82) of patients, and if biopsy samples with uncertainty regarding malignancy were excluded, the biopsy identified a lesion as being malignant in 84% (42 of 50) of patients. The biopsy results correlated with the final histologic grade as recorded from the resected specimen in only 33% (27 of 82) of patients. Among these 82 patients, 15 biopsies underestimated the final histologic grade. The median cartilage cap thickness for all benign osteochondromas was 0.5 cm (range 0.1 to 4.0 cm), and the median cartilage cap thickness for malignant peripheral chondrosarcomas was 8.0 cm (range 3.0 to 19 cm, difference of medians 7.5 cm; p < 0.01). LRFS was 49% (95% CI 35% to 63%) at 3 years for patients with malignant peripheral tumors with < 1-mm margins, and LRFS was 97% (95% CI 92% to 100%) for patients with malignant peripheral tumors with ≥ 1-mm margins (p < 0.01). DSS was 100% at 3 years for Grade 1 chondrosarcomas, 94% (95% CI 86% to 100%) at 3 years for Grade 2 chondrosarcomas, 73% (95% CI 47% to 99%) at 3 and 5 years for Grade 3 chondrosarcomas, and 20% (95% CI 0% to 55%) at 3 and 5 years for dedifferentiated chondrosarcomas (p < 0.01). DSS was 87% (95% CI 78% to 96%) at 3 years for patients with malignant peripheral tumors with < 1-mm margin, and DSS was 100% at 3 years for patients with malignant peripheral tumors with ≥ 1-mm margins (p = 0.01). Conclusion: A thin cartilage cap (< 3 cm) is characteristic of benign osteochondroma. The likelihood of a cartilage tumor being malignant increases after the cartilage cap thickness exceeds 3 cm. In our experience, preoperative biopsy results were not reliably associated with the final histologic grade or malignancy, being accurate in only 33% of patients. We therefore recommend observation for 2 years for patients with pelvic osteochondromas in which the cap thickness is < 1.5 cm and there is no associated pain. For patients with tumors in which the cap thickness is 1.5 to 3 cm, we recommend either close observation for 2 years or resection, depending on the treating physician’s decision. We recommend excision in patients whose pelvic osteochondromas show an increase in thickness or pain, preferably before the cartilage cap thickness is 3 cm. We propose that surgical resection of peripheral cartilage tumors in which the cartilage cap exceeds 3 cm (aiming for clear margins) is reasonable without preoperative biopsy; the role of preoperative biopsy is less helpful because radiologic measurement of the cartilage cap thickness appears to be accurately associated with malignancy. Biopsy might be helpful in patients in whom there is diagnostic uncertainty or when confirming the necessity of extensive surgical procedures. Future studies should evaluate other preoperative tumor qualities in differentiating malignant peripheral cartilage tumors from benign tumors. Level of Evidence: Level III, diagnostic study.


  • Open Access

    Chondrosarcoma of the Femur: Is Local Recurrence Influenced by the Presence of an Extraosseous Component?

    by Minna K. Laitinen, Michael C. Parry, Guy V. Morris, Robert J. Grimer, Vaiyapuri Sumathi, Jonathan D. Stevenson, Lee M. Jeys

    Background: Chondrosarcoma (CS) is the second most common surgically treated primary malignancy of the bone. The current study explored the effect of the margin and extraosseous tumor component in CS in the femur on local recurrence (LR), LR-free survival (LRFS), and disease-specific survival (DSS). Methods: Among 202 patients, 115 were in the proximal extremity of the femur, 4 in the corpus of the femur, and 83 in the distal extremity of femur; 105 patients had an extraosseous tumor component. Results: In the Kaplan–Meier analysis, factors significant for decreased LRFS were the extraosseous tumor component (p < 0.001), extraosseous tumor component arising from the superior aspect (p < 0.001), histological grade (p = 0.031), and narrow surgical margin < 3 mm (p < 0.001). Factors significantly affecting DSS were the histological grade (p < 0.001), extraosseous component (p < 0.001), LR (p < 0.001), metastases (p < 0.001), and surgical margin (p < 0.001). Conclusions: In CS of the femur, the presence of an extraosseous tumor component has a predictive role in LRFS, and extraosseous tumor component arising from the superior aspect was significant for decreased LRFS. Wide margins were more commonly achieved when the tumor had only an intraosseous component, and the rate of LR was significantly higher in cases with an extraosseous tumor component. When the extraosseous component arose from the superior aspect of the femur, LR occurred more frequently despite achieving adequate margins.


  • Mortality of high‐risk orthopaedic oncology patients during the COVID‐19 pandemic: A prospective cohort study

    by Jonathan D. Stevenson, Scott Evans, Guy Morris, Roger Tillman, Adesegun Abudu, Lee Jeys, Michael Parry

    Background and Objectives: Should the threshold for orthopaedic oncology surgery during the coronavirus disease‐2019 (COVID‐19) pandemic be higher, particularly in men aged 70 years and older? This study reports the incidence of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) during, respiratory complications and 30‐day mortality during the COVID‐19 pandemic.Methods: This prospective observational cohort study included 100 consecutive patients. The primary outcome measure was 14‐day symptoms and/or SARS‐CoV‐2 test. The secondary outcome was 30‐day postoperative mortality.Results: A total of 100 patients comprising 35 females and 65 males, with a mean age of 52.4 years (range, 16‐94 years) included 16 males aged greater than 70 years. The 51% of patients were tested during their admission for SARS‐CoV‐2; 5% were diagnosed/developed symptoms of SARS‐CoV‐2 during and until 14 days post‐discharge; four were male and one female, mean age 41.2 years (range, 17‐75 years), all had primary malignant bone or soft‐tissue tumours, four of five had received immunosuppressive therapy pre‐operatively. The 30‐day mortality was 1% overall and 20% in those with SARS‐CoV‐2. The pulmonary complication rate was 3% overall.Conclusions: With appropriate peri‐operative measures to prevent viral transmission, major surgery for urgent orthopaedic oncology patients can continue during the COVID‐19 pandemic. These results need validating with national data to confirm these conclusions.


  • Open Access

    Navigation in Musculoskeletal Oncology: An Overview

    by Guy Vernon Morris, Jonathan D. Stevenson, Scott Evans, Michael C. Parry, Lee Jeys

    The domain name Ijoonline.com is for sale. Call BuyDomains at 844-896-7299 to get a price quote and get your business online today!